Trinity Biotech plc to Announce Q1 2024 Financial Results
Conference Call Scheduled for Thursday, May 23, 2024 at 8:30 AM ET.
Get Alerts TRIB Hot Sheet
Join SI Premium – FREE
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the first quarter 2024 on Thursday, May 23, 2024 at 8:30 AM ET.
Conference Call Dial-In & Webcast Information
| Date: | Thursday, May 23, 2024 |
| Time: | 8:30 AM ET |
| United States: | 1-877-407-0784 |
| International: | 1- 201-689-8560 |
| Conference ID: Webcast:Call me™: | 13746798webcast linkhttps://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6 |
About Trinity Biotech Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com
| Contact: | Trinity Biotech plc | LifeSci Partners, LLC | ||
| Des Fitzgerald | Eric Ribner | |||
| (353)-1-2769800 | (1)-646-751-4363 | |||
| E-mail [email protected] |
Source: Trinity Biotech plc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wall Street sees Muse as Meta’s next big catalyst after Connect event
- Fastly’s 14% AI spike was a mirage; Here’s the edge stock Citi says you should own
- Docker Launches Cloud Sandboxes, Extending Secure AI Agent Isolation Beyond the Laptop
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share